What Ruxandra Teslo thinks about design

@ruxandra-teslo · 14 positions · On ppll ↗

Geneticist by training and writer on science, medicine and policy. She holds a PhD in genomics, writes at Ruxandra's Substack and for Works in Progress, and co-founded Clinical Trial Abundance, a project arguing that the binding constraint on new medicines is how trials are run rather than how drugs are designed.

Ruxandra Teslo did not write this page.

We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.

Filter design · Newest first

Topic

All 14AI and science 2innovation 2AI alignment 1design 1Psychotherapy 1venture capital 1

Sort

NewestOldest

Only Ruxandra Teslo on design. See everyone on design

1 dated position, 2026, in their own words. Our reading of what Ruxandra Teslo has said — not written or endorsed by them.

1 position so far — this page is not yet offered to search engines.

1. 28 Feb 2026

   Our readingBetter drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is.

   Their wordsEven if AI can help design more effective drugs, timelines will not compress until we solve the operational and regulatory bottlenecks of trials.

   ↗A response to Dario Amodei on AI & clinical trialswritingruxandrabio.com 2nd of 5 in this piece